AUROPHARMA

Aurobindo Pharma has approved a ₹800 crore share buyback at ₹1,475 per share, offering roughly a 10% premium over the previous closing price. The record date for eligibility has been set as 17 April 2026. Why It Matters: Buybacks typically signal management confidence in the company’s valuation It can improve earnings per share (EPS) and shareholder returns Often acts as a sentiment booster in the short term Investor Takeaway: Buyback announcements are generally viewed positively, but investors should monitor: Cash flow sustainability Debt levels Future growth outlook Alternate Stock